一项盲法终点的随机对照试验:含天然活性成分的Sanyrene用于预防接受放疗患者放射性皮炎
这项随机对照试验纳入102例接受放疗(≥50 Gy)的乳腺癌或头颈部癌患者,1:1随机分入Sanyrene组或对照干预组(DaBao®,透明质酸与维生素E复合物)。Sanyrene组≥2级放射性皮炎发生率为22%,对照干预组为67.3%(P<0.001)。试验提示Sanyrene可有效预防严重放射性皮炎并改善皮肤相关生活质量。
要点
- Sanyrene组≥2级放射性皮炎发生率为22%,对照干预组为67.3%(P<0.001)。
- Sanyrene组到达≥2级放射性皮炎的中位时间较对照干预组长,HR为0.231(95%CI:0.116-0.458,P<0.001)。
- 两组3级放射性皮炎发生率分别为对照干预组20.4%与Sanyrene组8.0%(P=0.076)。
核心结论
- 本试验提示Sanyrene可有效预防接受放疗的乳腺癌或头颈部癌患者的严重放射性皮炎,并改善皮肤相关生活质量。
研究设计与样本
- 随机对照试验,纳入接受放疗(≥50 Gy)的乳腺癌或头颈部癌患者,按1:1随机分入Sanyrene组或对照干预组(DaBao®,透明质酸与维生素E复合物)。
- 共102例合格患者被随机分配。
- 主要终点为≥2级放射性皮炎的发生率。
- 试验注册号ChiCTR2100050910,注册日期2021年7月9日。
主要发现
- Sanyrene组≥2级放射性皮炎发生率为22%,对照干预组为67.3%(P<0.001)。
- 3级放射性皮炎发生率在对照干预组为20.4%,Sanyrene组为8.0%(P=0.076)。
- Sanyrene组到达≥2级放射性皮炎的中位时间较对照干预组长,风险比为0.231(95%CI:0.116-0.458,P<0.001)。
- 放疗结束时SD-16平均评分对照干预组为25 vs Sanyrene组为8.3,放疗后2周为22.9 vs 0.5,放疗后4周为4.2 vs 0,两组间差异均有统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized controlled study was conducted to evaluate the efficacy of Sanyrene® vs. control intervention (DaBao®, a complex of hyaluronic acid and Vitamin E) for acute radiation dermatitis in patients receiving radiotherapy. METHODS: Patients with breast cancer or head and neck cancer undergoing radiotherapy (≥ 50 Gy) were eligible. Participants were randomly assigned to either Sanyrene arm or control intervention arm in a ratio of 1:1. The primary endpoint was incidence rate of ≥ grade 2 radiation induced dermatitis. (Trial Registration: ChiCTR2100050910, registration date: 9/7/2021) RESULTS: A total of 102 eligible patients were randomly assigned into the study. The rate of ≥ grade 2 radiation dermatitis was 22% in Sanyrene group, as compared with 67.3% in the control intervention group (P<0.001). The incidence of grade 3 radiation dermatitis was 20.4% and 8.0% in control intervention group and Sanyrene group, respectively (P = 0.076). Patients in Sanyrene group had a longer median time to reach ≥ grade 2 radiation dermatitis compared to these in control intervention group, with hazard ratio of 0.231 (95%CI:0.116-0.458, p < 0.001). Mean score of SD-16 were much higher in control intervention group than Sanyrene group at end of radiotherapy (25 vs.8.3), 2 weeks after radiotherapy (22.9 vs. 0.5) and 4 weeks after radiotherapy (4.2 vs.0), with significantly statistical difference between two groups. CONCLUSIONS: This trial suggests that Sanyrene is effective on preventing serious radiation dermatitis and improving skin related quality of life in patients with breast cancer or head and neck cancer receiving radiotherapy.
引用
- Long X, Guo J, Yin Y, et al. A blinded-endpoint, randomized controlled trial of Sanyrene with natural active ingredient for prophylaxis of radiation dermatitis in patients receiving radiotherapy. Radiat Oncol. 2023. PMID: 37891689. doi:10.1186/s13014-023-02363-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。